ARVINAS, INC.
Close on Oct 19, 2026
- Market cap
- $476.98M
- P/E (TTM)
- 45.4
- Dividend yield
- –
Earnings
Next report expected Nov 4, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 4, 2026 | Before market open | $249.70M | $2.58 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 12, 2026 | Before market open | $15.60M | $-0.90 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Feb 24, 2026 | Before market open | $9.50M | $-1.10 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 5, 2025 | Before market open | $41.90M | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 6, 2025 | Before market open | $22.40M | $-0.84 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 1, 2025 | Before market open | $188.80M | $1.14 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Feb 11, 2025 | Before market open | $59.20M | $-0.63 | – |
| Q3 FY2024 Ended Sep 30, 2024 | Oct 30, 2024 | Before market open | $102.40M | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Jul 30, 2024 | Before market open | – | – | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 7, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Feb 27, 2024 | Before market open | – | – | – |
Press releases
Announcements Arvinas filed with the SEC
Arvinas Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
looking statements should not be relied upon as representing Arvinas’ views as of any date subsequent to the date of this release. Contacts: Investors: Jeff Boyle +1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Exit or restructuring costs · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Kirsten Owens +1 (203) 584-0307 [email protected]
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports Second Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports First Quarter 2025 Financial Results and Provides Corporate Update
Results of operations · Exit or restructuring costs · Other events · EX-99.1 to Form 8-K
Arvinas Shares New Preclinical Combination Data for the PROTAC BCL6 Degrader, ARV-393, at the 2025 American Association for Cancer Research Annual Meeting
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Presents First-in-Human Data for Investigational Oral PROTAC ARV-102 Demonstrating Blood-Brain Barrier Penetration, and Central and Peripheral LRRK2 Degradation
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Arvinas Reports Second Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Arvinas Reports First Quarter 2024 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Vepdegestrant program update - Phase 1b data: combination trial with palbociclib - Development plan update San Antonio Breast Cancer Symposium December 6, 2023 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Arvinas Announces Oversubscribed $350 Million Private Placement
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
Arvinas Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
+1 (347) 247-5089 [email protected] Media: Kirsten Owens +1 (203) 584-0307 [email protected]
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
AR Franchise Update Bavdegalutamide and ARV-766 October 22, 2023 Exhibit 99.2
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K